Standard Operating Procedure for Annual Reportable Change Assessment
| Department | Regulatory Affairs |
| SOP No. | RA/2026/670 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 11/04/2026 |
| Effective Date | 11/04/2026 |
| Review Date | 11/04/2028 |
Purpose
This Standard Operating Procedure (SOP) describes the systematic approach for conducting an annual reportable change assessment within the regulatory affairs framework. Its purpose is to ensure timely identification, evaluation, documentation, and reporting of any changes affecting approved pharmaceutical products, processes, documentation, or systems to maintain compliance with regulatory requirements and uphold product quality, safety, and efficacy.
Scope
This SOP applies to all functional areas involved in reportable change assessment across pharmaceutical products, dosage forms, manufacturing processes, validation, calibration, qualification, equipment operation, cleaning, sampling, warehousing, documentation, engineering, laboratory, quality assurance, quality control, utilities, and compliance activities that fall under regulatory oversight. This SOP excludes changes not impacting regulatory submissions or those considered minor and non-reportable per regional regulatory guidelines.
Responsibilities
The following roles are involved in the annual reportable change assessment process:
- Regulatory Affairs Personnel – responsible for conducting change identification, evaluation, classification, and preparing assessment reports.
- Quality Assurance – reviewing and approving change assessment documentation to ensure compliance with GMP and quality requirements.
- Subject Matter Experts (e.g., Manufacturing, Engineering, Laboratory) – providing technical input and supporting evidence for assessment.
- Document Control – maintaining proper documentation and version control of change assessment records.
- Management – overseeing the implementation of change management and authorizing submission of regulatory notifications.
Accountability
The Head of Regulatory Affairs is accountable for the implementation, compliance monitoring, periodic review, and overall effectiveness of this SOP. This role ensures escalation of significant findings to senior management and drives continuous improvement in the reportable change assessment process.
Procedure
1. Preparation and Prerequisites:
- Gather all relevant data related to changes observed during the reporting period, including deviations, investigations, validation findings, equipment changes, process updates, supplier modifications, and documentation revisions.
- Review applicable regulatory guidelines and sponsor commitment letters to determine reportability criteria.
- Ensure access to prior annual report submissions and change logs for reference.
2. Change Identification and Data Collection:
- Engage cross-functional teams to identify all changes that occurred in the reporting period.
- Collect supporting documents such as deviation reports, validation summaries, calibration records, manufacturing batch records, and supplier communications.
3. Change Evaluation and Classification:
- Assess each change against established regulatory frameworks (e.g., ICH, FDA, EMA) and company internal criteria.
- Classify changes as reportable or non-reportable, determining the reporting category (e.g., immediate notification, annual report inclusion, variation submission).
- Check for impact on product quality, safety, efficacy, and regulatory commitments.
4. Documentation and Review:
- Prepare a comprehensive Annual Reportable Change Assessment document summarizing identified changes, evaluation rationale, classification decisions, and proposed reporting actions.
- Circulate the document for review and approval through Quality Assurance and the Regulatory Affairs Head.
- Incorporate any feedback and finalize the assessment report.
5. Regulatory Notification and Record Retention:
- Initiate timely submission of required notifications or variations to regulatory authorities in accordance with their timelines and formats.
- Ensure proper filing and archival of all assessment documents, regulatory submissions, review comments, and approvals per document retention policy.
6. Deviation Handling and Continuous Improvement:
- Investigate any discrepancies or deviations identified during the assessment process and document corrective and preventive actions.
- Review the effectiveness of the assessment annually and update the SOP or process as needed to enhance compliance and operational efficiency.
7. Closure:
- Confirm closure of all reporting activities and escalate any pending or critical issues to management for resolution.
- Communicate outcomes of the assessment to relevant stakeholders to ensure awareness and readiness for future changes.
All steps shall be executed in accordance with Good Manufacturing Practices (GMP), internal quality standards, and applicable regulatory requirements to maintain data integrity, transparency, and audit readiness.
Abbreviations
GMP – Good Manufacturing Practice
ICH – International Council for Harmonisation
FDA – Food and Drug Administration
EMA – European Medicines Agency
SOP – Standard Operating Procedure
QA – Quality Assurance
RA – Regulatory Affairs
Documents
The following documents are required to support the Annual Reportable Change Assessment process:
- Annual Reportable Change Log (Annexure-1)
- Change Assessment Summary Report (Annexure-2)
- Regulatory Notification Submission Checklist (Annexure-3)
References
- ICH Q12 – Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
- FDA Guidance for Industry – Changes to an Approved NDA or ANDA
- EMA Guideline on the details of the various categories of variations
- Company Quality Management System Documentation
- Applicable Pharmacopoeial Standards
- Internal Change Control Procedures
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Annual Reportable Change Log
Purpose: To maintain a detailed log of all changes identified during the reporting period for assessment of reportability.
| Change ID | Description of Change | Date of Change | Functional Area | Reportability Status | Comments |
|---|---|---|---|---|---|
| CHG-2026-001 | Update to equipment calibration frequency | 10/03/2026 | Engineering | Reportable | Requires annual notification |
| CHG-2026-002 | Change in supplier for raw material X | 22/01/2026 | Procurement | Reportable | Variation submission planned |
| CHG-2026-003 | Revision of cleaning procedure SOP | 05/02/2026 | Quality Assurance | Non-Reportable | No regulatory impact |
Annexure-2: Change Assessment Summary Report
Purpose: To summarize the evaluation, classification, and decisions related to reportable changes identified during the year.
| Change ID | Description | Assessment Date | Assessment Result | Recommended Reporting Action | Reviewed By |
|---|---|---|---|---|---|
| CHG-2026-001 | Update to equipment calibration frequency | 15/03/2026 | Change may impact product quality | Include in Annual Report | QA Reviewer |
| CHG-2026-002 | Change in supplier for raw material X | 25/01/2026 | Requires regulatory variation submission | Submit Variation | QA Reviewer |
Annexure-3: Regulatory Notification Submission Checklist
Purpose: To verify completeness and compliance of regulatory notification submissions related to reportable changes.
| Submission ID | Change ID | Submission Date | Authority | Submission Type | Status | Remarks |
|---|---|---|---|---|---|---|
| SUB-2026-101 | CHG-2026-001 | 20/03/2026 | FDA | Annual Report | Accepted | No queries raised |
| SUB-2026-102 | CHG-2026-002 | 30/01/2026 | EMA | Variation Submission | Under Review | Additional data requested |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 11/04/2026 | 1.0 | Initial issue | New SOP creation |